Kymera Therapeutics (KYMR) Net Income towards Common Stockholders (2019 - 2026)
Kymera Therapeutics (KYMR) reported Net Income towards Common Stockholders of -$69.2 million for Q1 2026, down 5.57% year-over-year from -$73.3 million in Q1 2025, and up 20.4% quarter-over-quarter from -$87.0 million in Q4 2025.
Kymera Therapeutics (KYMR) Net Income towards Common Stockholders (2019 - 2026) Analysis & Trends
Kymera Therapeutics (KYMR) has 8 years of Net Income towards Common Stockholders data on file, last reported at -$69.2 million in Q1 2026.
- Net Income towards Common Stockholders for Q1 2026 came in at -$69.2 million, down 5.57% year-over-year; the trailing twelve-month figure through Mar 2026 was -$315.0 million (down 30.77% YoY), and the FY2025 annual result was -$311.4 million, down 39.08% from the prior year.
- Net Income towards Common Stockholders advanced to -$69.2 million in Q1 2026 per KYMR's latest filing, from -$87.0 million in the prior quarter.
- Over five years, Net Income towards Common Stockholders peaked at -$14.4 million in Q4 2023 and troughed at -$87.0 million in Q4 2025.
- A 5-year average of -$53.3 million and a median of -$48.6 million in 2024 frame the typical range for Net Income towards Common Stockholders.
- The sharpest annual moves came in 2023 and 2024: Net Income towards Common Stockholders surged 58.79% in 2023, then tumbled 392.43% in 2024.
- A 5-year view of Net Income towards Common Stockholders shows it stood at -$34.9 million in 2022, then surged by 58.79% to -$14.4 million in 2023, then slumped by 392.43% to -$70.8 million in 2024, then declined by 22.94% to -$87.0 million in 2025, then advanced by 20.4% to -$69.2 million in 2026.
- Business Quant data shows KYMR's Net Income towards Common Stockholders at -$69.2 million in Q1 2026, -$87.0 million in Q4 2025, and -$82.2 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Income (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | -26.94 Mn |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | -13.56 Mn |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | 2.50 Mn |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | -3.63 Mn |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | -14.46 Mn |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | -1.50 Mn |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | 1.03 Bn |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | -56.48 Mn |
| 10 | Kymera Therapeutics | 8.84 Bn | 8.19 Bn | - | -69.23 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -69.23 Mn |
| Dec 31, 2025 | -86.98 Mn |
| Sep 30, 2025 | -82.18 Mn |
| Jun 30, 2025 | -76.61 Mn |
| Mar 31, 2025 | -65.58 Mn |
| Dec 31, 2024 | -70.75 Mn |
| Sep 30, 2024 | -62.49 Mn |
| Jun 30, 2024 | -42.06 Mn |
| Mar 31, 2024 | -48.56 Mn |
| Dec 31, 2023 | -14.37 Mn |
| Sep 30, 2023 | -52.87 Mn |
| Jun 30, 2023 | -38.80 Mn |
| Mar 31, 2023 | -40.93 Mn |
| Dec 31, 2022 | -34.87 Mn |
| Sep 30, 2022 | -43.00 Mn |
| Jun 30, 2022 | -40.26 Mn |
| Mar 31, 2022 | -36.97 Mn |
| Dec 31, 2021 | -34.05 Mn |
| Sep 30, 2021 | -28.71 Mn |
| Jun 30, 2021 | -24.66 Mn |